1. Scrip
  2. >>Scrip Perspectives

Five Clinical Trial Hits Of 2023

 
• By Alexandra Shimmings

The biopharma industry’s fate lies largely in its R&D successes and failures. Here, Scrip looks at five clinical trial successes that will shape their sponsors’ futures and got readers clicking in 2023.    

target
• Source: Shutterstock

Sanofi and Regeneron Pharmaceuticals, Inc. are now well positioned to add a new blockbuster-sized indication to the labelling for their behemoth anti-inflammatory Dupixent (dupilumab), namely chronic obstructive pulmonary disease (COPD), following successful readouts for two identical Phase III trials this year.

The first of these, BOREAS, in March confounded skepticism surrounding the usefulness of biologics in this challenging respiratory condition in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Scrip Perspectives

Top 12 Pharma Companies: Pfizer Tops The Leaderboard Again

 
• By Eleanor Malone

The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.

Scrip Asks... What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area Advances

 
• By Eleanor Malone

Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.

M&A Takeoff May Be Delayed, Experts Predict

 
• By Jessica Merrill

All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.

10 Clinical Trials To Look Out For In 2025

 
• By Alexandra Shimmings

Scrip surveys some of the more interesting Phase III clinical trial readouts expected this year.

More from Scrip

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

 
• By Joseph Haas

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 
• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat

 
• By Andrew McConaghie

Rivals Mineralys could be first to file but AstraZeneca is banking on its cardiovascular market know-how to lead the emerging class.